Patents by Inventor Walter A. Blattler

Walter A. Blattler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
    Publication number: 20180155427
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: October 6, 2017
    Publication date: June 7, 2018
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
    Publication number: 20180086830
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 29, 2018
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody molecules to LAG-3 and uses thereof
    Patent number: 9908936
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 6, 2018
    Assignees: Novartis AG, Immutep S.A.S.
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody molecules to TIM-3 and uses thereof
    Patent number: 9884913
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: February 6, 2018
    Assignees: Novartis AG, DANA-FARBER CANCER INSITITUTE, INC., Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Antibody molecules to PD-1 and uses thereof
    Patent number: 9815898
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
    Publication number: 20170247456
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Applicants: Novartis AG, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES
    Publication number: 20170226220
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: January 23, 2017
    Publication date: August 10, 2017
    Inventors: Ravi V.J. CHARI, Walter A. BLATTLER
  • ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
    Publication number: 20170210804
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: March 24, 2017
    Publication date: July 27, 2017
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF
    Publication number: 20170198041
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Application
    Filed: February 14, 2017
    Publication date: July 13, 2017
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF
    Publication number: 20170190777
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Application
    Filed: March 17, 2017
    Publication date: July 6, 2017
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Antibody molecules to PD-1 and uses thereof
    Patent number: 9683048
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: June 20, 2017
    Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY MAYTANSINOID CONJUGATES
    Publication number: 20170106097
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: June 1, 2016
    Publication date: April 20, 2017
    Inventors: Walter BLATTLER, Ravi V.J. Chari, Mark Sliwkowski, Sharon Erickson, Ralph Schwall
  • Antibody molecules to TIM-3 and uses thereof
    Patent number: 9605070
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: March 28, 2017
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
    Publication number: 20150259420
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 17, 2015
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF
    Publication number: 20150218274
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Application
    Filed: January 30, 2015
    Publication date: August 6, 2015
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
    Publication number: 20150210769
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 30, 2015
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20150110816
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: June 4, 2014
    Publication date: April 23, 2015
    Applicants: GENENTECH, INC., IMMUNOGEN INC.
    Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Ralph SCHWALL
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20140212411
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 31, 2014
    Applicants: GENENTECH, INC., IMMUNOGEN, INC.
    Inventors: Walter BLATTLER, Ralph SCHWALL, Mark SLIWKOWSKI, Sharon ERICKSON, Ravi V.J. CHARI
  • METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES
    Publication number: 20140154804
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: February 4, 2014
    Publication date: June 5, 2014
    Applicant: IMMUNOGEN INC
    Inventors: Ravi V.J. CHARI, Walter A. BLATTLER
  • Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
    Patent number: RE44704
    Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 14, 2014
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler